HYAL2 and cancer: We determined for the first time that Zfra-binding Hyal-2+ CD3− CD19− Z spleen cells are responsive to Zfra stimulation for mounting against the growth of a broad spectrum of cancer cells in vivo, suggesting that a therapeutic approach can be developed using patients' own Z cells for cancer treatment.